Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients
| Autor: | P. García de la Peña-Lefebvre, C. Díaz-Miguel, A. Zea Mendoza, M. Valero Expósito, S. Rodríguez Rubio, J. Orte Martínez, Loreto Carmona, M.L. Gámir Gámir, J. Beltrán Gutiérrez |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Endothelin Receptor Antagonists Male Systemic disease medicine.medical_specialty Adolescent Systemic scleroderma Severity of Illness Index Scleroderma Rheumatology Internal medicine Immunopathology Skin Ulcer medicine Humans Pharmacology (medical) Prospective Studies Child Aged Sulfonamides Scleroderma Systemic integumentary system business.industry Bosentan Middle Aged medicine.disease Dermatology Connective tissue disease digestive system diseases respiratory tract diseases Surgery Treatment Outcome Tolerability Female business medicine.drug |
| Zdroj: | Rheumatology. 47:464-466 |
| ISSN: | 1462-0332 1462-0324 |
| DOI: | 10.1093/rheumatology/ken001 |
| Popis: | Objectives. Our objective was to evaluate the efficacy and tolerability of bosentan in patients with systemic sclerosis (SSc) who develop ulcers and healed ulcers. We also wanted to analyse the effect of bosentan on other skin and general outcome measurements. Methods. In the present prospective, observational, non-controlled study, we followed all patients with SSc who started treatment with bosentan for ischaemic ulcers and healed ulcers from January 2003 to June 2006 in our centre. We recorded skin and general outcome measurements at baseline and at 6 months. Results. Fifteen patients were included. After a median follow-up of 24.7 months (range: 4-36), there was a significant decrease in the number of ulcers. A trend towards efficacy was seen in the number of healed ulcers and in the severity of ulcers. No significant effect was seen in other skin and general outcome measurements. Toxicity related to bosentan included mild transitory events and one toxic hepatitis. Conclusion. Bosentan may be a safe long-term alternative for treating the recurrence of skin ulcers and healed ulcers in SSc patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|